Clinical Trial Update: Paclitaxel Plus L-778,123 in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphomas [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating Paclitaxel in combination with L-778,123 for adults with recurrent or refractory solid tumors or lymphomas has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Lymphoma
• Solid Tumors

Drugs mentioned

• L-778,123
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific | Phase 1 | Status: COMPLETED